The ability of ESSH to modulate the expression of Ace, Nos3 and Agtr1a genes, along with its in vitro inhibitory activity against ACE, makes it (1) an essential dietary component and (2) a potent adjuvant in treating HT and cardiovascular diseases. The gene discussed is ACE; the disease is hematocrit.